Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study-Reference-Cited by-同舟云学术

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study

Published:2010 Issue: Volume: Page:NA-NA
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Lilly Michael B.,Ottmann Oliver G.,Shah Neil P.,Larson Richard A.,Reiffers Josy J.,Ehninger Gerhard,Müller Martin C.,Charbonnier Aude,Bullorsky Eduardo,Dombret Herve,Brigid Bradley-Garelik Mary,Zhu Chao,Martinelli Giovanni

Publisher

Wiley

Subject

Hematology

Reference32 articles.

1. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia;Faderl;Blood,1998

2. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products;Lugo;Science,1990

3. Philadelphia chromosome-positive acute lymphocytic leukemia;Radich;Hematol Oncol Clin North Am,2001

4. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia;Piccaluga;Cancer,2007

5. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias;Ottmann;Blood,2002

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia‐positive lymphoid leukemia to tyrosine kinase inhibitors;HemaSphere;2024-03

2. Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies;Current Treatment Options in Oncology;2023-12

3. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia;Leukemia;2023-04-19

4. Management of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (Ph-Like ALL);Pathogenesis and Treatment of Leukemia;2023

5. Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!;JCO Oncology Practice;2022-07